Alpelisib (BYL719)
99%
- Product Code: 99501
CAS:
1217486-61-7
| Molecular Weight: | 441.47 g./mol | Molecular Formula: | C₁₉H₂₂F₃N₅O₂S |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD22417085 | |
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20℃ |
Product Description:
Alpelisib is primarily used in the treatment of advanced or metastatic breast cancer, specifically in cases where the cancer is hormone receptor-positive (HR+), HER2-negative, and has a PIK3CA mutation. It is often prescribed in combination with fulvestrant, an estrogen receptor antagonist, to enhance its efficacy. The drug works by inhibiting the PI3K pathway, which is often overactive in these types of cancers, thereby slowing tumor growth and progression. Alpelisib is particularly beneficial for patients who have previously undergone endocrine therapy but have seen their cancer progress. Its targeted approach helps in managing the disease more effectively, offering a therapeutic option for those with specific genetic mutations.
Product Specification:
| Test | Specification |
|---|---|
| APPEARANCE | White to off-white powder or crystals |
| PURITY | 98.5-100 |
| Infrared spectrum | Conforms to Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.001 | 10-20 days | $53.16 |
+
-
|
| 0.005 | 10-20 days | $132.89 |
+
-
|
| 0.025 | 10-20 days | $316.45 |
+
-
|
| 0.100 | 10-20 days | $777.42 |
+
-
|
Alpelisib (BYL719)
Alpelisib is primarily used in the treatment of advanced or metastatic breast cancer, specifically in cases where the cancer is hormone receptor-positive (HR+), HER2-negative, and has a PIK3CA mutation. It is often prescribed in combination with fulvestrant, an estrogen receptor antagonist, to enhance its efficacy. The drug works by inhibiting the PI3K pathway, which is often overactive in these types of cancers, thereby slowing tumor growth and progression. Alpelisib is particularly beneficial for patients who have previously undergone endocrine therapy but have seen their cancer progress. Its targeted approach helps in managing the disease more effectively, offering a therapeutic option for those with specific genetic mutations.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
$0.00
$0.00
Total :